Reduced endogenous endothelin-1-mediated vascular tone in chronic renal failure

Kidney International

Volumn 55, Issue 2, 1999, Pages 613-620

  Hand, Malcolm F ^a   Haynes, William G ^a   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Blood pressure; BQ 123; Endothelin receptors; Hypertension; Renal failure; Vasoconstriction

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; NORADRENALIN; PHOSPHORAMIDON; PROTEINASE; THIORPHAN;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; IMMUNOREACTIVITY; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL;

EID: 0032910612     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00291.x     Document Type: Article

References (33)

1. 1. YANAGISAWA M, KURIHAWA H, KIMURA S, TOMOBE Y, KOBAYASHI M, MITSUI Y, YAZAKI Y, GOTO K, MASAKI T: A novel potent vasoconstrictor peptide produced by endothelial cells. Nature 332:411-415, 1988
2. 2. XU D, EMOTO N, GIAID A, SLAUGHTER C, KAW S, DE WIT D, YANAGISAWA M: ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78:473-485, 1994
3. 3. GRAY GA, WEBB DJ: The therapeutic potential of endothelin receptor antagonists in cardiovascular disease. Pharmacol Ther 72:109-148, 1996
4. 4. HAYNES WG, WEBB DJ: Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344:852-854, 1994
5. 5. RUBANYI GM, POLOKOFF MA: Endothelins: Molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol Rev 46:325-415, 1994
6. B receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 92:357-363, 1995
7. 7. HAYNES WG, FERRO CJ, O'KANE KP, SOMERVILLE D, LOMAX CC, WEBB DJ: Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 93:1860-1870, 1996
8. 8. KOYAMA H, TABATA T, NISHIZAWA Y, INOUE T, MORII H, YAMAJI T: Plasma endothelin levels in patients with uraemia. Lancet 333:991-992, 1989
9. 9. WARRENS AN, CASSIDY MJD, TAKAHASHI K, GHATEI MA, BLOOM SR: Endothelin in renal failure. Nephrol Dial Transplant 5:418-422, 1990
10. 10. WEBB DJ, COCKCROFT JR: Plasma immunoreactive endothelin in uraemia. (letter) Lancet 1:1211, 1989
11. 11. MIYAUCHI T, SUZUKI N, KURIHARA T, YAMAGUCHI I, SUGISHITA Y, MATSUMOTO H, GOTO K, MASAKI T: Endothelin-1 and endothelin-3 play different roles in acute and chronic alterations of blood pressure in patients with chronic haemodialysis. Biochem Biophys Res Commun 178:276-281, 1991
12. 12. DAVENPORT AP, ASHBY MJ, EASTON P, ELLA S, BEDFORD J, DICKERSON C, NUNEZ DJ, CAPPER SJ, BROWN MJ: A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: Comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci 78:261-264, 1990
13. 13. FERRO CJ, HAYNES WG, HAND MF, WEBB DJ: The vascular endothelin and nitric oxide systems in essential hypertension. (abstract) J Hypertens 14(Suppl 1):S50, 1996
14. 14. BARRAZUETA JR, BHAGAT K, VALLANCE P, MACALLISTER RJ: Dose and time dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm. Br J Clin Pharmacol 44:569-571, 1997
15. A) receptor antagonist in conscious rats. J Cardiovasc Pharmacol 20:940-948, 1992
16. 16. IKEGAWA R, MATSUMURA Y, TSUKAHARA Y, TAKAOKAM, MORIMOTO S: Phosphoramidon inhibits the generation of endothelin-1 from exogenously applied big endothelin-1 in cultured vascular endothelial cells and smooth muscle cells. FEBS Lett 293:45-48, 1991
17. 17. MCMAHON EG, PALOMO MA, MOORE WM: Phosphoramidon blocks the pressor activity of big endothelin [1-39] and lowers blood pressure in spontaneously hypertensive rats. J Cardiovasc Pharmacol 17(Suppl 7):S29-S33, 1991
18. 18. WHITNEY RJ: The measurement of volume changes in human limbs. J Physiol (Lond) 121:1-27, 1953
19. 19. WIINBERG N, WALTER-LARSON S, ERIKSEN C, NIELSEN PE: An evaluation of semi-automatic blood pressure manometers against intra-arterial blood pressure. J Ambulatory Monit 1:303-309, 1988
20. 20. EVANS CE, HAYNES RB, GOLDSMITH CH, HEWSON SA: Home blood pressure-measuring devices: A comparative study of accuracy. J Hypertens 7:133-142, 1989
21. 21. HAND MF, HAYNES WG, JOHNSTONE HA, ANDERTON JL, WEBB DJ: Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 48:806-813, 1995
22. 22. ROLINSKI B, BOGNER SJ, GOEBEL FD: Determination of endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine. Res Exp Med 194:9-24, 1994
23. 23. NEWBY DE, JALAN R, MASUMORI S, HAYES PC, BOON NA, WEBB DJ: Peripheral vascular tone in patients with cirrhosis: Role of the renin-angiotensin and sympathetic nervous systems. Cardiovasc Res 38:221-228, 1998
24. 24. GREENFIELD ADM, PATTERSON GC: Reaction of the blood vessels of the human forearm to increases in transmural pressure. J Physiol (Lond) 125:508-524, 1954
25. 25. WEBB DJ: The pharmacology of human blood vessels in vivo. J Vasc Res 32:2-15, 1995
26. 26. COLLIER JG, LORGE RE, ROBINSON BF: Comparison of the effects of tolmesoxide (RX71107), diazoxide, hydralazine, prazosin, glyceryl trinitrate and sodium nitroprusside on forearm arteries and dorsal hand veins of man. Br J Clin Pharmacol 5:35-44, 1978
27. A receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 94:2131-2137, 1996
28. 28. CANNAN CR, BURNETT JC JR, LERMAN A: Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. Circulation 93:646-651, 1996
29. 29. SAITO Y, KAZUWA N, SHIRAKAMI G, MUKOYAMA M, HOSODA K, SUGA S, OGAWA Y, IMURA H: Endothelin in patients with chronic renal failure. J Cardiovasc Pharmacol 17(Suppl 7):S437-S439, 1991
30. 30. SHICHIRI M, HIRATA Y, ANDO K, EMORI T, OHATA K, KIMOTO S, OGURA M, INOUE A, MARUMO F: Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 15:493-496, 1990
31. 31. VERHAAR MC, STRACHAN FE, NEWBY DE, CRUDEN NL, KOOMANS HA, RABELINK TJ, WEBB DJ: Endothelin-A receptor antagonist-mediated vasodilatation is inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97:752-756, 1998
32. 32. HAND MF, HAYNES WG, WEBB DJ: Hemodialysis and L-arginine, but not D-arginine, corrects renal failure associated endothelial dysfunction. Kidney Int 53:1068-1077, 1998
33. 33. BENJAMIN N, CALVER A, COLLIER J, ROBINSON B, VALLANCE P, WEBB D: Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 25:918-923, 1995